Carboplatin/etoposide

  • PDF / 169,744 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 80 Downloads / 175 Views

DOWNLOAD

REPORT


1 S

Neutropenia and febrile urinary tract infection: case report A 67-year-old woman developed neutropenia and febrile urinary tract infection during treatment with carboplatin and etoposide for small-cell lung cancer (SCLC) [outcomes not stated]. The woman presented to the emergency room with uncontrolled diabetes and degradation of her general status for a few months. Blood tests revealed hyponatraemia. She was initiated on fluid restriction, and was discharged after normalisation of natraemia. After one month, she started complaining about gait unsteadiness, a loss of coordination in her lower limbs, leading to falls, pain in both feet and ankles, and tingling. Thereafter, she was hospitalised due to worsening of symptoms. She was diagnosed with mild orthostatic hypotension with no appropriate rise in HR. Due to the severity, she was treated with unspecified corticosteroids, cyclophosphamide and immune globulin initially. She was diagnosed with SCLC and paraneoplastic subacute sensory neuropathy based on pathological studies, and was treated with cycles of carboplatin and etoposide [dosages and routes not stated] every 3 weeks. Subsequently, she developed a febrile urinary tract infection associated with neutropenia between third and fourth cycles of chemotherapy. She then had a brain haemorrhage and became hemiplegic. She received a palliative care, and died in the following week [immediate cause of death not stated]. Hean V, et al. Paraneoplastic subacute sensory neuropathy with triple positive antineuronal antibodies associated with small-cell lung cancer. BMJ Case Reports 13: No. 8, 803517153 2020. Available from: URL: http://doi.org/10.1136/bcr-2020-235668

0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 21 Nov 2020 No. 1831

Data Loading...